Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation
Main finding · Incident AFResult — go to the resultHazard ratio 0.60 95% CI 0.19–1.92Authors' conclusion
There was an overall trend towards lower incidence and prevalence of AF following treatment of SH, supporting the need for larger scale studies.
Study context
- Population
- Outpatients ≥18 years with biochemical subclinical hyperthyroidism (SH) diagnosed 2000–2021, without prior atrial fibrillation (AF), hypothyroidism, thyroid cancer, pituitary disease or pregnancy2,169 screened
- Participants
- 360 outpatients
- Exposure
- Treatment of SH vs no treatment
- Treatedn = 131
- Untreatedn = 229reference
- Outcome
- Incident AF
- Follow-up
- Mean 4.27 years
Methodological detailspharmacoepidemiologic
- Pharmacoepidemiologic
Main finding
As reported in the abstract
Hazard ratio
0.60
95% CI 0.19–1.92
P = 0.39
Events by group
Treatedvs Untreated
HR 0.60 (95% CI 0.19–1.92); P = 0.39
Observational data: associations, not effects.
Secondary outcomes
Incident AF, sensitivity analysis (2 patients with AF <30 days after starting SH treatment reassigned to untreated) · sensitivity analysis
P = 0.02
AF incidence Treated 0.4%/year · Untreated 1.8%/year
| Outcome | HR (CI) | P value | |
|---|---|---|---|
| Incident AF, sensitivity analysis (2 patients with AF <30 days after starting SH treatment reassigned to untreated)Sensitivity analysis | 0.25 (0.06–1.13) | P = 0.07 | |
| 0.050.21520Hazard ratio (log scale) |
| Outcome | P value |
|---|---|
| Incident AF, sensitivity analysis (2 patients with AF <30 days after starting SH treatment reassigned to untreated)Sensitivity analysis | P = 0.02 |
ECG and echocardiographic features associated with AF
- No differences in ECG or echocardiographic features
Original publication
Treatment of Subclinical Hyperthyroidism and Incident Atrial Fibrillation. Clin Endocrinol (Oxf). Published 14 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →